

**Announcement of Licensing by Japan Innovative Therapeutics, Inc. of Corneal Endothelium
Therapeutic Agents**

ActualEyes Inc. announces that the company has made a decision on acceptance from Japan Innovative Therapeutics, Inc. (hereinafter "JIT") of the exclusive enforcement right for corneal endothelium therapeutic agents which the Doshisha Doshisha University (hereinafter "Doshisha University") licensed to JIT, a consolidated subsidiary of D. Western Therapeutics Institute, Inc. (Aichi, Japan; President & CEO, Yuichi Hidaka; hereinafter "DWTI").

This agreement has been reached because we believe that the licensing of the exclusive enforcement right will be able to expand our development pipeline portfolio for corneal endothelium therapeutic agents, and further promote the research and development of regenerative medicine and drug therapy for corneal endothelial disorders, such as Fuchs endothelial corneal dystrophy and bullous keratopathy, which the company has focused on.

In association with the transfer of the right, the compensation will be paid to JIT, but the amount is not disclosed.

About D. Western Therapeutics Research Institute, Inc. (headquartered in Nagoya, Aichi Prefecture)

Based on the vision of bringing "Innovative New Drugs to the World from Japan," D. Western Therapeutics Institute (DWTI) is a bioventure aiming to deliver more effective new drugs as soon as possible to the patients who need them. DWTI's strength is in the discovery of kinase inhibitors, some of which already have been brought to market. Currently, DWTI is focusing on the field of ophthalmology, to aid in selection of the optimal treatment for each patient. For more information, please visit DWTI's website (www.dwti.co.jp/english/).

Contact information for inquiries about this announcement

ActualEyes Inc.

Masahiko Kato, Director, Management Department info@actualeyes.co.jp